Sub Banner Image

Capricor's Lead Duchenne Therapy Hits FDA Regulatory Roadblock

Market Impact

Vandana Singh

·

July 11, 2025

·

Benzinga

FDA rejected Capricor's BLA for Deramiocel due to insufficient evidence, requesting more clinical data to support approval for Duchenne therapy.

read more

More from

Benzinga

More

Market Impact

Articles

Trending News

Enjoy premium content in your inbox.

You're in! Check your email to learn more.
Oops! Something went wrong while submitting the form.